MDPH: COVID-19 Vaccine Live Q&A Sessions

MDPH Immunization Division

COVID-19 Vaccine Live Q&A Sessions

The MDPH Immunization Division is pleased to present the following live webinars on:

MDPH: COVID-19 Vaccine Live Q&A

Please register for any of the live webinars below:

COVID-19 Live Q&A

2/1/2021 - 1:00 PM - 2:00 PM

COVID-19 Live Q&A

2/22/2021 - 1:00 PM - 2:00 PM

COVID-19 Live Q&A

3/8/2021 - 1:00 PM - 2:00 PM

COVID-19 Live Q&A

3/22/2021 - 1:00 PM - 2:00 PM

These live Q&A sessions are meant to be a supplement to the training modules created by MDPH Immunization Division. Please be sure to review the attached training and supplemental resources listed below prior to joining the Q&A session.

MDPH COVID-19 VACCINE STORAGE & HANDLING AND ADMINISTRATION TRAINING

These training sessions are designed for health care providers, vaccine coordinators, and all health care personnel who handle and/or administer COVID-19 vaccines. It includes information current as of 12/31/2020. There is a focus on the Pfizer-BioNtech and Moderna COVID-19 vaccines. Please note: Information in these sessions is based on information currently available at the time of the recordings. More information will be released as it is received.

ADDITIONAL RESOURCES

Interim Clinical Considerations for Use of COVID-19 Vaccine: https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html
Product Info by US Vaccine (links to numerous vaccine-specific resources, such as standing orders, EUA, screening form, prep & administration summary, etc.): https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html
Management of Anaphylaxes: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html
COVID-19 Vaccine in MA: https://www.mass.gov/covid-19-vaccine
Map to Massachusetts COVID-19 Vaccine Sites: https://www.mass.gov/info-details/covid-19-vaccine-locations-for-individuals-currently-eligible-to-be-vaccinated
Moderna Vaccine Preparation and Administration Summary: https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/prep-and-admin-summary.pdf
CDC U.S. COVID-19 Vaccine Product Information page: https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html
Moderna Model Standing Orders: https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/standing-orders.pdf
CDC COVID-19 Vaccination Screening Form: https://www.cdc.gov/vaccines/covid-19/downloads/pre-vaccination-screening-form.pdf
Moderna Emergency Use Authorization Recipient Factsheet: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine
V-safe handout: https://www.mass.gov/doc/v-safe-information-sheet-pdf/download
CDC "What to Expect After Getting a COVID-19 Vaccine": https://www.cdc.gov/coronavirus/2019-ncov/vaccines/pdfs/321466-A_FS_What_Expect_COVID-19_Vax_Final_12.13.20.pdf
Vaccine Adverse Event Reporting System: https://vaers.hhs.gov/
CDC MMWR Early Release - Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020 https://www.cdc.gov/mmwr/volumes/70/wr/mm7002e1.htm?s_cid=mm7002e1_w
CDC MMWR Early Release - Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021 https://www.cdc.gov/mmwr/volumes/70/wr/mm7004e1.htm?s_cid=mm7004e1_e&ACSTrackingID=USCDC_921-DM47045&ACSTrackingLabel=MMWR%20Early%20Release%20-%20Vol.%2070%2C%20January%2022%2C%202021&deliveryName=USCDC_921-DM47045
New Vaccine Graphics Stop COVID-19 – Vaccine graphics | Mass.gov
New The COVID-19 Vaccine Provider FAQ was updated January 15, 2021
New COVID-19 mRNA Vaccines – What Clinic Personnel Need to Know, a side-by-side comparison of Pfizer-BioNTech and Moderna COVID-19 vaccines
Visit www.mass.gov/CovidVaccineProviders for vaccine provider FAQ; detailed guidance on vaccine management and administration; and CDC and FDA resources such as v-safe After Vaccination Health Checker.
Answers to FAQ’s from the general public
EUA fact sheets for providers and caregivers, available in multiple languages
MIIS FAQ for providers: https://www.miisresourcecenter.com/pages/ResourceCenterFaq
CDC MMWR Early Release - Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020
COVID-19 Vaccine Overview: Learn the basics of COVID-19 vaccine Emergency Use Authorization (EUA) and vaccine storage, handling, and administration in CDC’s course.
Visit CDC Clinician Outreach and Communication Activity for webinar recordings and slide sets on vaccination and other timely clinical topics.

CDC’s Guidance for Use of COVID-19 Vaccines and Management of Anaphylaxis

Ensure necessary supplies available to manage anaphylaxis, especially sufficient quantities of epinephrine in prefilled syringes or autoinjectors.
Screen potential vaccine recipients to identify persons with contraindications and precautions
Implement recommended post-vaccination observation periods, either 15 or 30 minutes depending on each patient’s previous history of allergic reactions.
Ensure that health care providers can recognize the signs and symptoms of anaphylaxis early
Immediately treat suspected anaphylaxis with intramuscular epinephrine; because of the acute, life-threatening nature of anaphylaxis. There are no contraindications to epinephrine administration.
Patients experiencing anaphylaxis should be transported to facilities where they can receive appropriate medical care.
All patients should be instructed to seek immediate medical care if they develop signs or symptoms of an allergic reaction after their observation period ends and they have left the vaccination location.
Health care providers can play an important role in vaccine safety by being vigilant in recognizing and reporting adverse events after immunization to VAERS at https://vaers.hhs.gov/reportevent.html